Immune aspects of sepsis and hope for new therapeutics

Current Infectious Disease Reports

Volumn 14, Issue 5, 2012, Pages 474-483

  LaRosa, Steven P ^a   Opal, Steven M ^b,c  

^a Beverly Hospital   (United States)

^b BROWN UNIVERSITY   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Apheresis; Co inhibitory immune signals; Co stimulatory immune signals; Hemoperfusion; Lipopolysaccharide; Sepsis; Sepsis interventions; Septic shock; Toll like receptors

Indexed keywords

ALKALINE PHOSPHATASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOFAB; DROTRECOGIN; ENZYME ACTIVATOR; HEPARIN; HYPERTENSIVE FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; POLYMYXIN B; PROTEINASE ACTIVATED RECEPTOR 1; RECOMBINANT THROMBOMODULIN; SIRTUIN 1; SRT 2379; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT STEM CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG TARGETING; ENZYME ACTIVATION; HELPER CELL; HEMOFILTRATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; MORTALITY; NONHUMAN; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

EID: 84870508804     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0276-2     Document Type: Article

References (66)

1. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a Primer. Crit Care Med. 2009;37(1):291-304.
2. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011. doi:10.1084/jem.20111354. This large study clearly demonstrates that the genes altered in acute systemic inflammation following severe injury follow similar patterns of upregulation and down regulation in patients that survive and those that do not survive. The differences in gene expression between survivors and non-survivors are primarily quantitative and not qualitative differences.
3. Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern recognition receptors. N Engl J Med. 2011;464 (1):60-70. This is an excellent review of the current state of knowledge about pattern recognition receptors, their microbial ligands, and the innate immune response to invasive pathogens.
4. Rathinam VAK, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395-403.
5. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845-58.
6. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol. 2004;4:499-511.
7. Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257-63.
8. Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie J. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 2001;69:875-84.
9. Arad G, Levy R, Nasie I, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biology. 2011;9:e1001149. This study elucidates the mechanism by which superantigens trigger the release of inflammatory cytokines resulting in septic shock.
10. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117-24.
11. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222-8.
12. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-2.
13. Coughlin SR. Thrombin signaling and protease-Activated receptors. Nature. 2000;407(6801):258-64.
14. Tressel SL, Kaneider NC, Foley C, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:1-15.
15. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-50.
16. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med. 2009;15(5):496-7. This is a superb review of the problem of sepsis-induced immune suppression and the potential therapeutic options to restore immune function in these vulnerable patients.
17. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813-22.
18. Hotchkiss RS, Opal SM. Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med. 2010;361(1):87-9.
19. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-605. This study provides compelling pathologic and immunologic evidence that sepsis-induced immune suppression is commonplace in septic patients and the dominant finding in human lethal septic shock.
20. Rauch PJ, Chudnovskiy A, Robbins CS, et al. Innate response activator B cells protect against microbial sepsis. Science. 2012. doi:10.1126/science. 1215173.
21. Newell MK, Tobin RP, Cabrera JH, et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B celldependent inflammation. J Leuk Biol. 2010;88:779-89.
22. Nathan C, Ding A. Non-resolving inflammation. Cell. 2010;140:871-82. This is an excellent review of the critical elements that regulate the host response to human septic and sterile inflammatory processes. The mechanisms of immune and tissue-specific restoration of structure and function are examined in detail.
23. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354(11):1166-76.
24. Kasten KR, Tschop J, Adediran SG, Hideman DA, Caldwell CC. T cells are potent early mediators of the host response to sepsis. Shock. 2010;34(4):327-36.
25. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170-84.
26. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191-7.
27. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 869-74.
28. Ballina-Rosas M, Olofsson PS, Ochanni M, et al. Acetylcholinesynthesizing T Cells relay neural signals in a vagus nerve circuit. Science. 2011;334:98-101. This work points out the intricate interactions between Vagus nerve signals and anti-inflammatory signals within the spleen that regulate cellular immune function.
29. Wong CHY, Jenne CN, Lee W-Y, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334:101-5. This remarkable study identifies the role of the sympathetic nervous system in regulating the function of NKT cells and the important contribution of these uncommon T cells to bacterial clearance.
30. Mattsby-Baltzer I, Bergstrom T, McCrea K, et al. Affinity aphaeresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). J Microbiol Biotechnol. 2011;21(6):659-64.
31. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. This is a well performed meta-Analysis of the randomized and non-randomized studies of the Polymyxin B immobilized filter. These results are the basis for the need for adequately powered, randomized, controlled clinical trial.
32. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock, the EUPHAS randomized controlled trial. JAMA. 2009;301:2445-52.
33. Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phophatase in vivo. Am J Pathol. 1997;151:1163-9.
34. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-65.
35. Verweij WR, Bentala H, van der Vlag AH, et al. Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice. Shock. 2004;22:174-9.
36. Van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun. 2005;73:4309-14.
37. Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37:417-23.
38. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16:R14. This recently completed trial of alkaline phosphatase suggests that the benefit may be due to nephroprotective properties.
39. Teleman D, Chung CS, Ayala A, et al. AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis. Crit Care. 2011;15(3):35.
40. Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-Alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006;34:2271-81.
41. Yang H, Feldser H, Zhang W, et al. SIRT1 activators promote p65 deacetylation and suppress TNFα stimulated NF-κB activation. Abstract presented at the 2011 ASBMB Meeting in Washington D.C. in April 2011.
42. Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation. Available at http://clinicaltrials.gov/ct2/show/NCT01416376. Accessed 11 April 2012.
43. Zingarelli B, Cook JA. Peroxisome proliferator-Activated receptorgamma is a new therapeutic target in sepsis and inflammation. Shock. 2005;23:393-9.
44. Collin M, Murch O, Thiemermann C. Peroxisome proliferatoractivated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med. 2006;34:1131-8.
45. Kaplan JM, Denenberg A, Monaco M, et al. Changes in peroxisome proliferator-Activated receptor-gamma activity in children with septic shock. Intensive Care Med. 2010;36:123-30.
46. Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-Activated receptor-β/in septic shock. Am J Respir Crit Care Med. 2010;182:1506-15.
47. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa activated in adults with septic shock. N Engl J Med. 2012;366:2055-64. This follow up study with recombinant human activated protein C failed to replicate improved survival in treated patients as observed in the original phase 3 trial. This drug has been taken off the market as a result of this study.
48. Mohri M, Sugimoto E, Sata M, et al. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation-A comparison with other anticoagulants. Thromb Haemost. 1999;82:1687-93.
49. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41.
50. Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med. 2003;31(1 Suppl):S97-104.
51. Guo RF, Riedemann NC, Ward PA. Role of C5a-C5aR interaction in sepsis. Shock. 2004;21:1-7.
52. Taylor FB, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J Cell Mol Med. 2012;16(4):672-82. This recently completed animal model of sepsis elucidates a second stage in sepsis whereby organ failure may be mediated by complement activation.
53. Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002-10.
54. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788-92.
55. Igonin AA, Protsenko DN, Gennadiy GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40:770-7.
56. Weaver JG, Rouse MS, Steckelberg JM, Badley AD. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB J. 2004;18:1185-91.
57. Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010;184:3768-79.
58. Inoue S, Unsinger J, Davis CG, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction and improves survival in sepsis. J Immunol. 201;184 (3):1401-1409.
59. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233-40.
60. Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207 (12):2551-9.
61. Zhao G, Jin H, Li J, et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 2009;22(2):131-8.
62. Laporte R, Kohan A, Heitzmann J, et al. Pharmacological characterization of FE 202158, a novel, potent, selective, and short acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. JPET. 2011;337(3):786-96.
63. Cribbs S, Matthay MA, Martin GS. Stem cells in sepsis and acute lung injury. Crit Care Med. 2010;38:2379-85. An excellent review of the multiple mechanisms of action of adult human stem cells. The paper further summarizes the experience to date with adult stem cells in animal models of sepsis and acute lung injury.
64. Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047-57.
65. Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; in press.
66. Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med. 2012;366(3):201-4.